Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies

Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies

Nov 15, 2014

Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-ain457-secukinumab-showed-significant-symptom-improvement-two-pivotal-phase-iii-ankylosing-spondylitis-studies-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-ain457-secukinumab-showed-significant-symptom-improvement-two-pivotal-phase-iii-ankylosing-spondylitis-studies-0